Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report.

Bissonnette L, April PM, Dumais R, Boire G, Roux S.

Bone. 2013 Oct;56(2):406-9. doi: 10.1016/j.bone.2013.07.012. Epub 2013 Jul 17.

PMID:
23871749
2.

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP.

J Bone Miner Res. 2014 Jan;29(1):1-23. doi: 10.1002/jbmr.1998. Epub 2013 Oct 1. Review.

3.

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Nieves JW, Cosman F.

Curr Osteoporos Rep. 2010 Mar;8(1):34-9. doi: 10.1007/s11914-010-0007-2. Review.

PMID:
20425089
4.
5.

Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.

Zanchetta MB, Diehl M, Buttazzoni M, Galich A, Silveira F, Bogado CE, Zanchetta JR.

J Bone Miner Res. 2014 Apr;29(4):999-1004. doi: 10.1002/jbmr.2107.

6.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee.

N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.

7.

Pelvic fractures associated with long-term bisphosphonate therapy - case report.

Patel V, Graves L, Lukert B.

J Musculoskelet Neuronal Interact. 2013 Jun;13(2):251-4.

8.

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research.

J Bone Miner Res. 2010 Nov;25(11):2267-94. doi: 10.1002/jbmr.253. Erratum in: J Bone Miner Res. 2011 Aug;26(8):1987.

9.

Atypical forearm fractures associated with long-term use of bisphosphonate.

Moon J, Bither N, Lee T.

Arch Orthop Trauma Surg. 2013 Jul;133(7):889-92. doi: 10.1007/s00402-013-1760-3. Epub 2013 Apr 26.

PMID:
23619919
10.

Rare non-traumatic periprosthetic femoral fracture with features of an atypical femoral fracture: a case report.

Niikura T, Lee SY, Sakai Y, Kuroda R, Kurosaka M.

J Med Case Rep. 2015 May 6;9:103. doi: 10.1186/s13256-015-0590-z.

11.

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.

Gedmintas L, Solomon DH, Kim SC.

J Bone Miner Res. 2013 Aug;28(8):1729-37. doi: 10.1002/jbmr.1893. Review.

12.

Bone cross-sectional geometry is not associated with atypical femoral fractures in Asian female chronic bisphosphonate users.

Chou AC, Ng AC, Png MA, Chua DT, Ng DC, Howe TS, Koh JS.

Bone. 2015 Oct;79:170-5. doi: 10.1016/j.bone.2015.06.003. Epub 2015 Jun 9.

PMID:
26067179
13.

Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?

Tarazona-Santabalbina FJ, Aguilella-Fernández L.

Aging Clin Exp Res. 2013 Oct;25(5):605-9. doi: 10.1007/s40520-013-0137-3. Epub 2013 Sep 12.

PMID:
24026625
14.

Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.

Hagen JE, Miller AN, Ott SM, Gardner M, Morshed S, Jeray K, Alton TB, Ren D, Abblitt WP, Krieg JC.

J Bone Joint Surg Am. 2014 Nov 19;96(22):1905-9. doi: 10.2106/JBJS.N.00075.

PMID:
25410509
15.

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.

Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH.

J Bone Miner Res. 2011 May;26(5):993-1001. doi: 10.1002/jbmr.288.

16.

Atypical femur fracture during bisphosphonate drug holiday: a case series.

Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R.

Osteoporos Int. 2015 Jun;26(6):1755-8. doi: 10.1007/s00198-015-3063-8. Epub 2015 Apr 2.

PMID:
25832177
17.

Identifying atypical femoral fractures--a retrospective review.

Juby AG, Crowther S, Cree M.

Calcif Tissue Int. 2014 Nov;95(5):405-12. doi: 10.1007/s00223-014-9908-x. Epub 2014 Sep 11.

PMID:
25209972
18.

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM.

Osteoporos Int. 2009 Aug;20(8):1353-62. doi: 10.1007/s00198-008-0805-x. Epub 2008 Dec 9.

19.

Burden of bisphosphonate-associated femoral fractures.

Shkolnikova J, Flynn J, Choong P.

ANZ J Surg. 2013 Mar;83(3):175-81. doi: 10.1111/ans.12018. Epub 2012 Dec 6.

PMID:
23216704
20.

Treatment of femoral fracture nonunion after long-term bisphosphonate use.

Grady MK, Watson JT, Cannada LK.

Orthopedics. 2012 Jun;35(6):e991-5. doi: 10.3928/01477447-20120525-51.

PMID:
22691683

Supplemental Content

Support Center